Home
Companies
Catalysts
Deep Dives
Pluvicto
lutetium Lu177 vipivotide tetraxetan
APPROVED
Drug Profile
Modality
Radioligand therapy
Route
IV
Therapy Area
Oncology
Launch
2022-03-23
US LOE
2037-03-01
Peak Sales Est
$4000M
Formulations
[{"id":"pluvicto-iv","doses":"7.4 GBq (200 mCi)","route":"IV","setting":"INFUSION_CENTER","frequency
Companies
NVS
(ORIGINATOR)
100%
Mechanism: PSMA-targeting
Expert:
Ligand targeting prostate-specific membrane antigen (PSMA) conjugated to therapeutic radioisotope (Lu-177 or Ac-225)
Everyday:
Targets a protein on prostate cancer cells to deliver radiation directly to tumors
Targets: ["PSMA"]
Revenue History
Period
Revenue ($M)
2024
$1,420M
2025
$1,850M
Q4 2024
$400M
Q4 2025
$520M
Programs (2)
Indication
Stage
Key Study
Regional Status
mCRPC (PSMA+)
APPROVED
VISION
[{"stage":"APPROVED","region":"US","approval_date":"2022-03"}]
mHSPC (PSMA+)
FILED
PSMAfore
[]
Upcoming Catalysts (2)
Pluvicto - Pre-Chemo mCRPC - FDA Approval
Q1 2026
225Ac-PSMA-617 - mCRPC - Ph3 - Start
2026
Notes
Lu-177 PSMA radioligand therapy for mCRPC. First-in-class. Supply constrained.
Data from Supabase · Updated 2026-03-24